Form 4: Evoke Pharma Director Todd C. Brady Acquires Stock Options
SEC Form 4 Filing
Director Todd C. Brady acquired stock options in Evoke Pharma, Inc. on May 21, 2025.
Summary
- On May 21, 2025, Todd C. Brady, a director of Evoke Pharma Inc., acquired stock options to purchase 1,187 shares of common stock at an exercise price of $3.453 per share.
- These options vest on the one-year anniversary of the grant date, contingent upon continued service to the issuer.
- Following the transaction, Brady directly owns 8,238 shares.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard transaction; director acquiring stock options is generally viewed as a positive sign, but it's not a major event.
Positives
- The acquisition of stock options by a director signals confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.
Stakeholder Impact
- The acquisition of stock options by a director can positively influence shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Date of earliest transaction: acquisition of stock options. |
| 05/21/2025 | Date of grant of stock options. |
| 05/20/2035 | Expiration date of the stock options. |
| 05/22/2025 | Date of signature on the Form 4 filing. |
Keywords
Evoke Pharma, Stock Options, Director, Form 4, Beneficial Ownership, EVOK, Brady, Todd C. Brady
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.